Related Experiment Video
Updated: Apr 29, 2026

Isolation and Flow Cytometric Analysis of Immune Cells from the Ischemic Mouse Brain
Published on: February 12, 2016
OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice
Munehisa Shimamura1, Hironori Nakagami1, Mariana K Osako1
1Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka 565-0871, Japan;
Abstract:
Osteoprotegerin (OPG) is a soluble secreted protein and a decoy receptor, which inhibits a receptor activator of nuclear factor κB (NF-κB) ligand (RANKL)/the receptor activator of NF-κB (RANK) signaling. Recent clinical studies have shown that a high-serum-OPG level is associated with unfavorable outcome in ischemic stroke, but it is unclear whether OPG is a culprit or an innocent bystander. Here we demonstrate that enhanced RANKL/RANK signaling in OPG(-/-) mice or recombinant RANKL-treated mice contributed to the reduction of infarct volume and brain edema via reduced postischemic inflammation. On the contrary, infarct volume was increased by reduced RANKL/RANK signaling in OPG(-/-) mice and WT mice treated with anti-RANKL neutralizing antibody. OPG, RANKL, and RANK mRNA were increased in the acute stage and were expressed in activated microglia and macrophages. Although enhanced RANKL/RANK signaling had no effects in glutamate, CoCl2, or H2O2-stimulated neuronal culture, enhanced RANKL/RANK signaling showed neuroprotective effects with reduced expression in inflammatory cytokines in LPS-stimulated neuron-glia mixed culture, suggesting that RANKL/RANK signaling can attenuate inflammation through a Toll-like receptor signaling pathway in microglia. Our findings propose that increased OPG could be a causal factor of reducing RANKL/RANK signaling and increasing postischemic inflammation. Thus, the OPG/RANKL/RANK axis plays critical roles in controlling inflammation in ischemic brains.
Insights
High osteoprotegerin (OPG) levels worsen ischemic stroke outcomes. Enhanced receptor activator of nuclear factor κB ligand (RANKL)/RANK signaling reduces brain damage and inflammation, suggesting OPG may be a causal factor.
Area of Science:
- Neuroscience
- Immunology
- Molecular Biology
Background:
- Osteoprotegerin (OPG) inhibits RANKL/RANK signaling.
- High serum OPG correlates with poor ischemic stroke outcomes.
- The role of OPG in ischemic stroke pathogenesis is unclear.
Purpose of the Study:
- To investigate the causal role of OPG and RANKL/RANK signaling in ischemic stroke.
- To determine the impact of OPG/RANKL/RANK axis on postischemic inflammation and brain injury.
Main Methods:
- Utilized OPG knockout (OPG-/-) mice and wild-type (WT) mice.
- Administered recombinant RANKL and anti-RANKL neutralizing antibody.
- Assessed infarct volume, brain edema, and inflammatory markers.
- Examined OPG, RANKL, and RANK mRNA expression in brain tissue.
- Conducted neuronal and neuron-glia mixed cultures.
Main Results:
- Enhanced RANKL/RANK signaling reduced infarct volume and brain edema by decreasing inflammation.
- Reduced RANKL/RANK signaling increased infarct volume.
- OPG, RANKL, and RANK were upregulated in the acute stroke stage, found in microglia and macrophages.
- RANKL/RANK signaling demonstrated neuroprotective effects in LPS-stimulated cultures by reducing inflammatory cytokines.
Conclusions:
- Increased OPG may causally increase postischemic inflammation by inhibiting RANKL/RANK signaling.
- The OPG/RANKL/RANK axis is critical in regulating inflammation within ischemic brains.
- Targeting the OPG/RANKL/RANK pathway could offer therapeutic strategies for ischemic stroke.

